A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations
2020-306-GLOB1
Phase 1 other active
Quick answer
A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations for - Acute myeloid leukemia - Myelodysplastic syndrome/ Myeloproliferative neoplasm - Angio-immunoblastic T-cell lymphoma - Other mIDH-positive hematological malignancies (other than tumor types mentioned above) is a Phase 1 program (other) at Hutchmed Europe B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hutchmed Europe B.V.
- Indication
- - Acute myeloid leukemia - Myelodysplastic syndrome/ Myeloproliferative neoplasm - Angio-immunoblastic T-cell lymphoma - Other mIDH-positive hematological malignancies (other than tumor types mentioned above)
- Phase
- Phase 1
- Modality
- other
- Status
- active